Drew Armstrong

Pfizer’s make-or-break quarter

Tues­day could be the most im­por­tant quar­ter­ly re­port of Pfiz­er CEO Al­bert Bourla’s ca­reer. When the drug­mak­er re­leas­es third-quar­ter re­sults around 7 a.m., the world

Read More »

Post-Hoc: Novo’s obesity enemies

This week, Roche joined Eli Lil­ly in com­ing out against a deal that would add sig­nif­i­cant new man­u­fac­tur­ing ca­pac­i­ty to No­vo Nordisk, to help it

Read More »